+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

New England Journal of Medicine 366(3): 207-215

Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors. We performed a molecular analysis to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib. An analysis of an independent validation set and functional studies with BRAF inhibitors in the presence of the prevalent RAS mutation was also performed. Among 21 tumor samples, 13 had RAS mutations (12 in HRAS). In a validation set of 14 samples, 8 had RAS mutations (4 in HRAS). Thus, 60% (21 of 35) of the specimens harbored RAS mutations, the most prevalent being HRAS Q61L. Increased proliferation of HRAS Q61L-mutant cell lines exposed to vemurafenib was associated with mitogen-activated protein kinase (MAPK)-pathway signaling and activation of ERK-mediated transcription. In a mouse model of HRAS Q61L-mediated skin carcinogenesis, the vemurafenib analogue PLX4720 was not an initiator or a promoter of carcinogenesis but accelerated growth of the lesions harboring HRAS mutations, and this growth was blocked by concomitant treatment with a MEK inhibitor. Mutations in RAS, particularly HRAS, are frequent in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with vemurafenib. The molecular mechanism is consistent with the paradoxical activation of MAPK signaling and leads to accelerated growth of these lesions. (Funded by Hoffmann-La Roche and others; numbers, NCT00405587, NCT00949702, NCT01001299, and NCT01006980.).

(PDF emailed within 0-6 h: $19.90)

Accession: 055333395

Download citation: RISBibTeXText

PMID: 22256804

DOI: 10.1056/NEJMoa1105358

Related references

Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell & Melanoma Research 25(5): 569-572, 2013

COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Molecular Oncology 8(2): 250-260, 2014

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. Journal of Clinical Oncology 30(3): 316-321, 2012

Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. British Journal of Dermatology 169(6): 1310-1313, 2014

KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review. Annals of Surgical Oncology 20 Suppl 3(): S485-S491, 2014

Aggressive squamous cell carcinomas in patients treated with extracorporeal photopheresis for cutaneous T-cell lymphoma. Archives of Dermatology 131(10): 1211-1212, 1995

An unexpected spectrum of p53 mutations from squamous cell carcinomas in psoriasis patients treated with PUVA. Photochemistry & Photobiology. 66(2): 294-299,., 1997

Mutations of the p53 gene in basal cell carcinomas and cutaneous squamous cell carcinomas. Clinical Research 39(4): 815A, 1991

Age and clear eyes are associated with an increased risk of cutaneous squamous cell carcinomas in vemurafenib-treated melanoma patients. Melanoma Research 26(5): 487-491, 2016

A novel treatment approach for extensive, eruptive, cutaneous squamous cell carcinomas in a patient receiving BRAF inhibitor therapy for metastatic melanoma. Dermatologic Surgery 39(2): 341-344, 2013

Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatology 149(3): 322-326, 2013

Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?. Journal of Clinical Oncology 30(3): 329-330, 2012

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. Journal of Translational Medicine 14(): 95-95, 2016

Mutations in the p53 tumor suppressor gene in human cutaneous squamous cell carcinomas. Molecular Carcinogenesis 4(6): 445-449, 1991